{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T05:57:24Z","timestamp":1783749444356,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Independent Research Fund Denmark","award":["013400123B"],"award-info":[{"award-number":["013400123B"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Glucose-6-Phosphate Dehydrogenase deficiency (G6PDd) is a common genetic enzymopathy that can induce haemolysis triggered by various factors, including some anti-malarial drugs. Although many Point-of-Care (PoC) tests, such as Standard G6PD\u2122 are available to detect G6PDd, its pooled diagnostic test accuracy (DTA) remains unknown.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>To estimate the DTA of StandG6PD-BS at various thresholds of G6PDd, a systematic review with a DTA meta-analysis were conducted, searching EMBASE, MEDLINE, and SciELO databases up to April 4, 2024.The included studies were those that measured G6PD activity using StandG6PD-BS (reference test) and spectrophotometry (gold standard) in patients suspected of having G6PDd. The risk of bias (RoB) of the studies was assessed using the QUADAS-2 tool and the certainty of evidence (CoE) with the GRADE approach. For the estimation of within-study DTA, a random-effect bivariate meta-analysis was performed to determine the pooled sensitivity and specificity for 30%, 70%, and 80% enzyme levels\u2019 thresholds, and a graphical analysis of the heterogeneity using crosshair and Confidence Regions on receiver operating characteristic (ROC) space plots.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After screening 2496 reports, four studies were included with 7864 participants covering all thresholds. Two studies had high RoB in QUADAS-2 domains 2 and 3, and the others had low RoB, with low, moderate, and high heterogeneity at the 30%, 70%, and 80% thresholds, respectively. The pooled sensitivity was 99.1%, 95.7%, and 90% for 30%, 70%, and 80% thresholds, respectively. The pooled specificity was 97.4%; 92.9%; and 89.0% for 30%, 70%, and 80% thresholds, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>StandG6PD-BS is a PoC test with high sensitivity and specificity to detect G6PDd at different thresholds.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12936-024-05144-1","type":"journal-article","created":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T19:02:41Z","timestamp":1730574161000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Diagnostic accuracy of the point-of-care standard G6PD test\u2122 (SD Biosensor) for glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6420-7797","authenticated-orcid":false,"given":"Juan Camilo","family":"Mart\u00ednez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9430-3912","authenticated-orcid":false,"given":"Viviana","family":"V\u00e9lez-Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9876-0248","authenticated-orcid":false,"given":"Mary","family":"Lopez-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4030-4255","authenticated-orcid":false,"given":"Daniel F.","family":"Pati\u00f1o-Lugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0751-8932","authenticated-orcid":false,"given":"Ivan D.","family":"Florez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,2]]},"reference":[{"key":"5144_CR1","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/B978-0-12-407826-0.00004-7","volume":"81","author":"RE Howes","year":"2013","unstructured":"Howes RE, Battle KE, Satyagraha AW, Baird JK, Hay SI. G6PD deficiency: global distribution, genetic variants and primaquine therapy. The epidemiology of Plasmodium vivax. Adv Parasitol. 2013;81:133\u2013201.","journal-title":"Adv Parasitol"},{"key":"5144_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.638885","volume":"12","author":"G Bancone","year":"2021","unstructured":"Bancone G, Chu CS. G6PD variants and haemolytic sensitivity to primaquine and other drugs. Front Pharmacol. 2021;12: 638885.","journal-title":"Front Pharmacol"},{"key":"5144_CR3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.bcmd.2008.12.005","volume":"42","author":"ET Nkhoma","year":"2009","unstructured":"Nkhoma ET, Poole C, Vannappagari V, Hall SA, Beutler E. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells Mol Dis. 2009;42:267\u201378.","journal-title":"Blood Cells Mol Dis"},{"key":"5144_CR4","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1186\/1475-2875-12-418","volume":"12","author":"RE Howes","year":"2013","unstructured":"Howes RE, Dewi M, Piel FB, Monteiro WM, Battle KE, Messina JP, et al. Spatial distribution of G6PD deficiency variants across malaria-endemic regions. Malar J. 2013;12:418.","journal-title":"Malar J"},{"key":"5144_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003561","volume":"18","author":"CS Chu","year":"2021","unstructured":"Chu CS, White NJ. The prevention and treatment of Plasmodium vivax malaria. PLoS Med. 2021;18: e1003561.","journal-title":"PLoS Med"},{"key":"5144_CR6","volume-title":"World Malaria Report 2023","author":"WHO","year":"2023","unstructured":"WHO. World Malaria Report 2023. Geneva: World Health Organization; 2023."},{"key":"5144_CR7","volume-title":"Testing for G6PD deficiency for safe use of primaquine in radical cure of P. vivax and P. ovale malaria: policy brief","author":"WHO","year":"2016","unstructured":"WHO. Testing for G6PD deficiency for safe use of primaquine in radical cure of P. vivax and P. ovale malaria: policy brief. Geneva: World Health Organization; 2016."},{"key":"5144_CR8","volume-title":"Malaria Policy Advisory Committee Meeting. Point-of-care G6PD testing to support safe use of primaquine for the treatment of vivax malaria","author":"WHO","year":"2015","unstructured":"WHO. Malaria Policy Advisory Committee Meeting. Point-of-care G6PD testing to support safe use of primaquine for the treatment of vivax malaria. Geneva: World Health Organization; 2015."},{"key":"5144_CR9","doi-asserted-by":"publisher","first-page":"854","DOI":"10.4269\/ajtmh.14-0194","volume":"91","author":"N LaRue","year":"2014","unstructured":"LaRue N, Kahn M, Murray M, Leader BT, Bansil P, McGray S, et al. Comparison of quantitative and qualitative tests for glucose-6-phosphate dehydrogenase deficiency. Am J Trop Med Hyg. 2014;91:854\u201361.","journal-title":"Am J Trop Med Hyg"},{"key":"5144_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0148172","volume":"11","author":"FE Espino","year":"2016","unstructured":"Espino FE, Bibit JA, Sornillo JB, Tan A, von Seidlein L, Ley B. Comparison of three screening test kits for G6PD enzyme deficiency: implications for its use in the radical cure of vivax malaria in remote and resource-poor areas in the Philippines. PLoS ONE. 2016;11: e0148172.","journal-title":"PLoS ONE"},{"key":"5144_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4269\/ajtmh.14-0298","volume":"92","author":"L Osorio","year":"2015","unstructured":"Osorio L, Carter N, Arthur P, Bancone G, Gopalan S, Gupta SK, et al. Performance of BinaxNOW G6PD deficiency point-of-care diagnostic in P. vivax-infected subjects. Am J Trop Med Hyg. 2015;92:22\u20137.","journal-title":"Am J Trop Med Hyg"},{"key":"5144_CR12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1186\/s12936-017-2017-3","volume":"16","author":"B Ley","year":"2017","unstructured":"Ley B, Bancone G, von Seidlein L, Thriemer K, Richards JS, Domingo GJ, et al. Methods for the field evaluation of quantitative G6PD diagnostics: a review. Malar J. 2017;16:361.","journal-title":"Malar J"},{"key":"5144_CR13","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1590\/0037-8682-0134-2016","volume":"49","author":"MAM Brito","year":"2016","unstructured":"Brito MAM, Peixoto HM, de Almeida ACG, de Oliveira MRF, Romero GAS, Moura-Neto JP, et al. Validation of the rapid test Carestart(tm) G6PD among malaria vivax-infected subjects in the Brazilian Amazon. Rev Soc Bras Med Trop. 2016;49:446\u201355.","journal-title":"Rev Soc Bras Med Trop"},{"key":"5144_CR14","unstructured":"PATH. G6PD Operational Research Community of Practice. 2022."},{"key":"5144_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0011652","volume":"17","author":"W Adissu","year":"2023","unstructured":"Adissu W, Brito M, Garbin E, Macedo M, Monteiro W, Mukherjee SK, et al. Clinical performance validation of the STANDARD G6PD test: a multi-country pooled analysis. PLoS Negl Trop Dis. 2023;17: e0011652.","journal-title":"PLoS Negl Trop Dis"},{"key":"5144_CR16","doi-asserted-by":"crossref","unstructured":"Deeks JJ, Bossuyt PM, Leeflang MM, Takwoingi Y (editors). Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. Version 2.0. Cochrane, 2023.","DOI":"10.1002\/9781119756194"},{"key":"5144_CR17","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan\u2013-a web and mobile app for systematic reviews. Syst Rev. 2016;5:210.","journal-title":"Syst Rev"},{"key":"5144_CR18","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","volume":"155","author":"P Whiting","year":"2011","unstructured":"Whiting P, Rutjes A, Westwood M, Mallett S, Deeks J, Reitsma J, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529\u201336.","journal-title":"Ann Intern Med"},{"key":"5144_CR19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jclinepi.2019.12.020","volume":"122","author":"HJ Sch\u00fcnemann","year":"2020","unstructured":"Sch\u00fcnemann HJ, Mustafa RA, Brozek J, Steingart KR, Leeflang M, Murad MH, et al. GRADE guidelines: 21 part 1. Study design, risk of bias, and indirectness in rating the certainty across a body of evidence for test accuracy. J Clin Epidemiol. 2020;122:129\u201341.","journal-title":"J Clin Epidemiol"},{"key":"5144_CR20","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jclinepi.2019.12.021","volume":"122","author":"HJ Sch\u00fcnemann","year":"2020","unstructured":"Sch\u00fcnemann HJ, Mustafa RA, Brozek J, Steingart KR, Leeflang M, Murad MH, et al. GRADE guidelines: 21 part 2. Test accuracy: inconsistency, imprecision, publication bias, and other domains for rating the certainty of evidence and presenting it in evidence profiles and summary of findings tables. J Clin Epidemiol. 2020;122:142\u201352.","journal-title":"J Clin Epidemiol"},{"key":"5144_CR21","unstructured":"Doebler P. mada: meta-analysis of diagnostic accuracy [Internet]. 2020. https:\/\/cran.r-project.org\/package=mada"},{"key":"5144_CR22","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.jclinepi.2005.02.022","volume":"58","author":"JB Reitsma","year":"2005","unstructured":"Reitsma JB, Glas AS, Rutjes AWS, Scholten RJPM, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol. 2005;58:982\u201390.","journal-title":"J Clin Epidemiol"},{"key":"5144_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0257560","volume":"16","author":"S Pal","year":"2021","unstructured":"Pal S, Myburgh J, Bansil P, Hann A, Robertson L, Gerth-Guyette E, et al. Reference and point-of-care testing for G6PD deficiency: blood disorder interference, contrived specimens, and fingerstick equivalence and precision. PLoS ONE. 2021;16: e0257560.","journal-title":"PLoS ONE"},{"key":"5144_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009649","volume":"15","author":"S Zobrist","year":"2021","unstructured":"Zobrist S, Brito M, Garbin E, Monteiro WM, Clementino Freitas S, Macedo M, et al. Evaluation of a point-of-care diagnostic to identify glucose-6-phosphate dehydrogenase deficiency in Brazil. PLoS Negl Trop Dis. 2021;15: e0009649.","journal-title":"PLoS Negl Trop Dis"},{"key":"5144_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206331","volume":"13","author":"MS Alam","year":"2018","unstructured":"Alam MS, Kibria MG, Jahan N, Thriemer K, Hossain MS, Douglas NM, et al. Field evaluation of quantitative point of care diagnostics to measure glucose-6-phosphate dehydrogenase activity. PLoS ONE. 2018;13: e0206331.","journal-title":"PLoS ONE"},{"key":"5144_CR26","doi-asserted-by":"publisher","first-page":"213","DOI":"10.4269\/ajtmh.18-0612","volume":"100","author":"S Pal","year":"2018","unstructured":"Pal S, Bansil P, Bancone G, Hrutkay S, Kahn M, Gornsawun G, et al. Evaluation of a novel quantitative test for glucose-6-phosphate dehydrogenase deficiency: bringing quantitative testing for glucose-6-phosphate dehydrogenase deficiency closer to the patient. Am J Trop Med Hyg. 2018;100:213\u201321.","journal-title":"Am J Trop Med Hyg"},{"key":"5144_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003535","volume":"18","author":"N Nekkab","year":"2021","unstructured":"Nekkab N, Lana R, Lacerda M, Obadia T, Siqueira A, Monteiro W, et al. Estimated impact of tafenoquine for Plasmodium vivax control and elimination in Brazil: a modelling study. PLoS Med. 2021;18: e1003535.","journal-title":"PLoS Med"},{"key":"5144_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0010174","volume":"16","author":"B Ley","year":"2022","unstructured":"Ley B, Satyagraha AW, Kibria MG, Armstrong J, Bancone G, Bei AK, et al. Repeatability and reproducibility of a handheld quantitative G6PD diagnostic. PLoS Negl Trop Dis. 2022;16: e0010174.","journal-title":"PLoS Negl Trop Dis"},{"key":"5144_CR29","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1473-3099(13)70250-0","volume":"14","author":"PK Drain","year":"2014","unstructured":"Drain PK, Hyle EP, Noubary F, Freedberg KA, Wilson D, Bishai WR, et al. Evaluating diagnostic point-of-care tests in resource-limited settings. Lancet Infect Dis. 2014;14:239\u201349.","journal-title":"Lancet Infect Dis"},{"key":"5144_CR30","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1208\/s12249-021-02107-6","volume":"22","author":"F Jameel","year":"2021","unstructured":"Jameel F, Alexeenko A, Bhambhani A, Sacha G, Zhu T, Tchessalov S, et al. Recommended best practices for lyophilization validation 2021 Part II: process qualification and continued process verification. AAPS PharmSciTech. 2021;22:266.","journal-title":"AAPS PharmSciTech"},{"key":"5144_CR31","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12936-023-04559-6","volume":"22","author":"TH Aung","year":"2023","unstructured":"Aung TH, Suansomjit C, Tun ZM, Hlaing TM, Kaewkungwal J, Cui L, et al. Prevalence of G6PD deficiency and diagnostic accuracy of a G6PD point-of-care test among a population at risk of malaria in Myanmar. Malar J. 2023;22:143.","journal-title":"Malar J"},{"key":"5144_CR32","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.cll.2009.10.001","volume":"30","author":"LS Garcia","year":"2010","unstructured":"Garcia LS. Malaria. Clin Lab Med. 2010;30:93\u2013129.","journal-title":"Clin Lab Med"},{"key":"5144_CR33","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1080\/14656566.2022.2058394","volume":"23","author":"A Llanos-Cuentas","year":"2022","unstructured":"Llanos-Cuentas A, Manrrique P, Rosas-Aguirre A, Herrera S, Hsiang MS. Tafenoquine for the treatment of Plasmodium vivax malaria. Expert Opin Pharmacother. 2022;23:759\u201368.","journal-title":"Expert Opin Pharmacother"},{"key":"5144_CR34","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/tmi.12800","volume":"22","author":"HM Peixoto","year":"2017","unstructured":"Peixoto HM, Brito MAM, Romero GAS, Monteiro WM, de Lacerda MVG, de Oliveira MRF. Rapid diagnostic test for G6PD deficiency in Plasmodium vivax-infected men: a budget impact analysis based in Brazilian Amazon. Trop Med Int Health. 2017;22:21\u201331.","journal-title":"Trop Med Int Health"},{"key":"5144_CR35","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1001\/jama.2017.19163","volume":"319","author":"MDF McInnes","year":"2018","unstructured":"McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM, the PRISMA-DTA Group, et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. JAMA. 2018;319:388\u201396.","journal-title":"JAMA"},{"key":"5144_CR36","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s12936-017-1981-y","volume":"16","author":"B Ley","year":"2017","unstructured":"Ley B, Thriemer K, Jaswal J, Poirot E, Alam MS, Phru CS, et al. Barriers to routine G6PD testing prior to treatment with primaquine. Malar J. 2017;16:329.","journal-title":"Malar J"},{"key":"5144_CR37","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.3390\/pathogens11111328","volume":"11","author":"JD Brito-Sousa","year":"2022","unstructured":"Brito-Sousa JD, Murta F, Vitor-Silva S, Sampaio V, Mendes M, Souza B, et al. Quantitative G6PD deficiency screening in routine malaria diagnostic units in the Brazilian Amazon (SAFEPRIM): an operational mixed-methods study. Pathogens. 2022;11:1328.","journal-title":"Pathogens"},{"key":"5144_CR38","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12936-024-05050-6","volume":"23","author":"TH Barker","year":"2024","unstructured":"Barker TH, McBride GM, Dias M, Price C, Munn Z. Contextual factors and G6PD diagnostic testing: a scoping review and evidence and gap map. Malar J. 2024;23:241.","journal-title":"Malar J"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-024-05144-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-024-05144-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-024-05144-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T19:02:48Z","timestamp":1730574168000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-024-05144-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,2]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5144"],"URL":"https:\/\/doi.org\/10.1186\/s12936-024-05144-1","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,2]]},"assertion":[{"value":"30 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"327"}}